Leksum LLC, an early-stage life sciences company based in Boston, Massachusetts, has signed an agreement with the Department of Anesthesia, Intensive Care Medicine and Pain Medicine at the Medical University of Vienna. The agreement covers preparatory work leading up to Phase I/II first-in-human clinical trials for LK-ICU, a biologic therapy consisting of extracellular vesicles derived from bone marrow mesenchymal stromal cells. Phoenestra GmbH is a co-signatory to the agreement. The full announcement is available click here.
This development matters because it signals a critical step toward addressing ICU-acquired weakness, a debilitating condition that can prolong mechanical ventilation and significantly impair patient recovery. Preclinical studies of LK-ICU indicate an almost complete preservation of both diaphragm muscle fiber size and function during mechanical ventilation. Extended weaning from mechanical ventilation, often resulting from ICU-acquired weakness, is estimated to impact the quality-of-life of hundreds of thousands of patients a year in the U.S. and Europe. By preserving diaphragm function, LK-ICU could potentially shorten ventilator dependence, reduce complications, and improve long-term outcomes for critically ill patients.
The collaboration with the Medical University of Vienna, a leading European clinical research institution, provides Leksum with access to a robust patient population and expertise in anesthesia and intensive care. Leksum plans to start efforts under the agreement upon closing its Series A financing round. The planning phase is expected to last several months, after which the company intends to initiate first-in-human trials. Notably, Leksum intends to use European clinical data to support its U.S. regulatory path, which could streamline the approval process and accelerate availability for American patients.
Leksum's broader pipeline targets acquired muscle myopathies, including skeletal muscle conditions such as sarcopenia, cancer cachexia, and muscle loss due to the use of weight-loss drugs like GLP-1s. This agreement therefore represents not only a milestone for LK-ICU but also a validation of the company's platform approach to muscle preservation. For more information about Leksum, visit their website. The announcement was distributed by Reportable, Inc..
The implications of this agreement extend beyond the immediate trial. If LK-ICU proves successful in preserving diaphragm function, it could become a standard adjunct therapy in intensive care units, reducing the burden on healthcare systems and improving patient quality of life. Moreover, the partnership with a prestigious institution like the Medical University of Vienna lends scientific credibility and may attract further investment. As Leksum moves toward its Series A, the agreement underscores the growing interest in biologic solutions for muscle-wasting conditions. For patients and clinicians, this news offers hope that a therapy for ICU-acquired weakness may be on the horizon, potentially transforming critical care practices.
